Methods of using a pharmaceutical composition containing pirfenidone in sustained-release tablet form
The instant invention relates to a process for the preparation of a pharmaceutical composition in sustained-release tablet form comprising from 600 milligrams to 2400 milligrams of Pirfenidone (PFD), in such a way that the drug is bioavailable during an extended period of time of 12 hours from its administration. In this way, the anti-fibrotic and anti-inflammatory action of the drug Pirfenidone is optimized. Moreover, the instant invention offers advantages and a higher therapeutic efficacy compared to other pharmaceutical forms of Pirfenidone for oral administration and its therapeutic application in the regression of chronic renal failure secondary to primary glomerulosclerosis; it shows a better activity with regard to the reduction and/or regression of deleterious effects in breast capsular contracture observed after the surgical implantation of breast implants in humans and has an important anti-TNF-α and anti-TGF-β1 action for the treatment of hepatic fibrosis.
1. A method for treating liver cirrhosis comprising administering to a subject in need thereof, a composition in sustained-release tablet form comprising 100 mg to 2400 mg pirfenidone, microcrystalline cellulose, low viscosity hydroxypropylmethylcellulose (HPMC), high viscosity hydroxypropylmethylcellulose (HPMC), silicon dioxide, and sodium stearyl fumarate.
2. A method for treating liver cirrhosis comprising administering to a subject in need thereof, a composition in sustained-release tablet form comprising 100 mg to 2400 mg pirfenidone, wherein the sustained-release tablet has a bioavailability of up to 12 hours.
3. The method of claim 2 , wherein the composition comprises 600 mg of pirfenidone.
4. The method of claim 2 , wherein the composition comprises 400 mg of pirfenidone.
5. The method of claim 2 , wherein the composition comprises 600 mg to 2400 mg of pirfenidone.
6. The method of claim 1 , wherein the sustained-release tablet has a bioavailability of up to 12 hours.
7. The method of claim 2 , wherein the composition comprises 118.8 mg microcrystalline cellulose, 70.0 mg low viscosity hydroxypropylmethylcellulose (HPMC), 46.5 mg high viscosity hydroxypropylmethylcellulose (HPMC), 8.5 mg silicon dioxide, and 6.2 mg sodium stearyl fumarate.
8. The method of claim 2 , wherein the composition is administered for up to 6 months.
9. The method of claim 2 , wherein the composition is administered for up to 12 months.
10. The method of claim 2 , wherein the composition is administered for at least 12 months.
11. The method of claim 2 , wherein the composition is administered orally at least one time per day.
12. The method of claim 2 , wherein the composition is administered orally 2 times per day.
13. The method of claim 2 , wherein the composition is administered orally 3 times per day.
14. The method of claim 2 , wherein the composition is administered orally 1 to 4 times per day.
15. The method of claim 2 , wherein a daily dosage comprises 400 mg to 2400 mg of pirfenidone per day.
16. The method of claim 2 , wherein a daily dosage comprises up to 2400 mg of pirfenidone per day.
17. The method of claim 2 , wherein a daily dosage comprises up to 1400 mg per m 2 body surface area (BSA) of pirfenidone per day.
18. A method for treating liver fibrosis comprising administering to a subject in need thereof, a composition in sustained-release tablet form comprising 100 mg to 2400 mg pirfenidone, microcrystalline cellulose, low viscosity hydroxypropylmethylcellulose (HPMC), high viscosity hydroxypropylmethylcellulose (HPMC), silicon dioxide, and sodium stearyl fumarate.
19. The method of claim 18 , wherein the composition comprises 600 mg of pirfenidone.
20. The method of claim 18 , wherein the composition is administered orally 2 times per day.